WT1 peptide-major histocompatibility complex class I complex (WT1 peptide/MHC I complex)

The **WT1 peptide-major histocompatibility complex class I (MHC I) complex** refers specifically to the MHC class I molecule (most extensively studied as HLA-A*0201) presenting a short peptide derived from the Wilms tumor 1 protein (WT1), such as the WT1_126-134 epitope (RMFPNAPYL)[1][2][3]. The **WT1 protein** itself is a transcription factor implicated in normal development and highly overexpressed in a wide range of leukemias and solid tumors[3]. When peptides from WT1 are presented on MHC class I molecules at the tumor cell surface, they mark these cells as abnormal and enable recognition by **CD8+ cytotoxic T cells**, making the WT1 peptide/MHC I complex a validated **therapeutic target for immunotherapy**[1][2][3]. Targeting this complex has led to experimental peptide-based vaccines and TCR-like antibody or cell therapy approaches in cancer, particularly for tumors with high WT1 expression and appropriate HLA alleles[3]. The main therapeutic concept is to stimulate or engineer immune effector cells to recognize and kill tumor cells displaying the WT1 peptide/HLA complex. Structural studies have also guided design of peptide variants for improved immunogenicity and efficacy[1][2]. Caveats for therapy include variation in WT1 and HLA-A*0201 expression, the possibility of tumor immune escape, and risks of on-target off-tumor effects due to some WT1 expression in healthy tissues[3]. This target is therefore of major interest in cancer immunology and is considered one of the best-characterized tumor antigen/MHC complexes in translational research.

Other names

WT1 peptide-HLA-A2 complexWilms tumor 1 peptide-HLA-A*0201 complexWT1_126-134 peptide-MHC I complex

Induction of cytotoxic T cell response via antigen presentation, Immune recognition for elimination of WT1-expressing tumor cells, Targeting by engineered antibodies or CARs leading to immune-mediated tumor clearance